CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
用于肿瘤免疫治疗的 CAR-T 细胞——前路障碍与突破路径
英文原题：CAR-T cells for cancer immunotherapy-the barriers ahead and the paths through.
查看英文原题
CAR-T cells for cancer immunotherapy-the barriers ahead and the paths through.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
本文基于我们的经验和认识，讨论嵌合抗原受体（CAR）T 疗法临床应用迅速扩展过程中出现的主要问题和变化。过去几十年来，人们依次质疑 CAR-T 细胞诱导初始缓解的能力、安全性、维持长期持续存在和疗效的能力，以及产业化潜力。为应对这些挑战，领域内已取得显著进展，包括新型靶向策略、创新分子结构、对 CAR-T 和宿主免疫系统进行精细调控、与其他疗法联合，以及简化生产流程等。尽管问题尚未完全解决，已有合理路径可望突破这些障碍。本文介绍这些路径的近期进展，并展望可能的未来方向。
展开英文摘要原文
This review discusses the major concerns and changes emerged during the rapidly extended clinical application of chimeric antigen receptor (CAR) T therapy based on our experience and understanding. In the past decades, the CAR-T cells have been questioned, sequentially, about their capability of inducing initial remission, their safety profile, their ability to sustain long-term persistence and response, and their potential to be industrialized.
Significant advances, novel targeting strategies, innovative molecular structure, fine tuning of both CAR-T and host immune system, combination with other therapies, streamlined manufacturing, and etc. , have been made to overcome these challenges. Although not perfectly resolved, rational pathways have been proposed to pass through the barriers.
Here, we present the recent achievements on these pathways, and look into the possible future directions.
论文信息
- 作者
- Zhang Q、Zu C、Hu Y、Huang H
- 单位
- Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.China
- 文献类型
- 综述
- 期刊
- International reviews of immunology2022
- 原文标识
- PubMed 35635212 · DOI 10.1080/08830185.2022.2080820